Agios Pharmaceuticals, Inc. (AGIO) has a negative trailing P/E of -4.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -21.28%.
Criteria proven by this page:
Overall SharesGrow Score: 58/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -8.2 | -0.13 | 4.55 | 23.36 | - |
| 2017 | -8.5 | -0.26 | 7.09 | 61.92 | - |
| 2018 | -7.7 | 0.72 | 3.85 | 28.05 | - |
| 2019 | -7.0 | -0.72 | 4.47 | 24.30 | - |
| 2020 | -9.1 | 0.32 | 7.48 | 0.00 | - |
| 2021 | 1.2 | 0.04 | 1.54 | 0.00 | - |
| 2022 | -6.6 | 0.20 | 1.40 | 108.04 | - |
| 2023 | -3.5 | -0.07 | 1.53 | 46.21 | - |
| 2024 | 2.8 | -0.01 | 1.21 | 51.14 | - |
| 2025 | -3.8 | 0.02 | 1.32 | 29.21 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-5.07 | $69.89M | $-198.47M | -284% |
| 2017 | $-6.75 | $43.01M | $-314.67M | -731.6% |
| 2018 | $-6.03 | $94.39M | $-346.03M | -366.6% |
| 2019 | $-6.61 | $117.91M | $-396.61M | -336.4% |
| 2020 | $-4.86 | $203.2M | $-335.22M | -165% |
| 2021 | $26.55 | $0.00 | $1.6B | - |
| 2022 | $-1.36 | $14.24M | $-74.56M | -523.6% |
| 2023 | $-6.33 | $26.82M | $-352.09M | -1312.6% |
| 2024 | $11.64 | $36.5M | $673.73M | 1845.9% |
| 2025 | $-7.12 | $54.03M | $-412.78M | -764% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-6.63 | $-7.48 – $-5.79 | $91.25M | $73.01M – $105.7M | 8 |
| 2027 | $-5.11 | $-6.48 – $-3.34 | $233.47M | $164.77M – $299.41M | 9 |
| 2028 | $-3.42 | $-4.81 – $-2.16 | $371.78M | $366.83M – $376.73M | 8 |
| 2029 | $-2.35 | $-3.34 – $-1.33 | $502.32M | $334.06M – $665.01M | 6 |
| 2030 | $-0.06 | $-0.09 – $-0.04 | $666.11M | $442.98M – $881.85M | 6 |
